Allarity Therapeutics Inc
Change company Symbol lookup
Select an option...
ALLR Allarity Therapeutics Inc
SIVB SVB Financial Group
LYLT Loyalty Ventures Inc
NMRD Nemaura Medical Inc
LOGI Logitech International SA
BIOC Biocept Inc
KT KT Corp
SVRA Savara Inc
KA Kineta Inc
IMNM Immunome Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company. The Company is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The Company's products include dovitinib, stenoparib, and IXEMPRA (ixabepilone). The lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. The therapeutic candidate is stenoparib is a novel inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). The therapeutic candidate is IXEMPRA (ixabepilone) is a selective microtubule inhibitor. The DRP technology is a diagnostic platform that models human tumor biology and can help predict whether a cancer patient respond or not to a particular drug.

Closing Price
$0.1439
Day's Change
0.0389 (37.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.229
Day's Low
0.1301
Volume
(Heavy Day)
Volume:
83,434,571

10-day average volume:
8,156,624
83,434,571

Block/AfterPay (SQ) Alert: Afterpay Investors Receiving Block Shares Encouraged to Contact Johnson Fistel Regarding Investigation

1:28 pm ET January 9, 2023 (Globe Newswire) Print
Block/AfterPay (SQ) Alert: Afterpay Investors Receiving Block Shares Encouraged to Contact Johnson Fistel Regarding InvestigationGlobeNewswireJanuary 09, 2023

SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating Block, Inc. ("Block" or "the Company") (NYSE: SQ) on behalf of shareholders who received Block shares in exchange of Afterpay Ltd. shares (ASX: APT). The investigation focuses on whether any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors.

What if I Received Block common stock? If you received Block common stock in connection with the Afterpay merger and lost money, join our investigation now:

Click or paste the following web address into your browser to submit your losses:

https://www.johnsonfistel.com/investigations/block-inc

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471

There is no cost or obligation to you.

About Johnson Fistel, LLP:

Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson Fistel, LLP

Jim Baker, 619-814-4471

jimb@johnsonfistel.com



Primary Logo

comtex tracking

COMTEX_422382075/2010/2023-01-09T13:28:10

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.